About: Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck
Creator	Liu, Jia Lu, Mengji Roggendorf, Michael Kosinska, Anna
Source	PMC
abstract	Infection with hepatitis B virus (HBV) may lead to subclinical, acute or chronic hepatitis. In the prevaccination era, HBV infections were endemic due to frequent mother to child transmission in large regions of the world. However, there are still estimated 240 million chronic HBV carriers today and ca. 620,000 patients die per year due to HBV-related liver diseases. Recommended treatment of chronic hepatitis B with interferon-α and/or nucleos(t)ide analogues does not lead to satisfactory results. Induction of HBV-specific T cells by therapeutic vaccination or immunomodulation may be an innovative strategy to overcome virus persistence. Vaccination with commercially available HBV vaccines in patients with or without therapeutic reduction of viral load did not result in effective immune control of HBV infection, suggesting that combination of antiviral treatment with new formulations of therapeutic vaccines is needed. The woodchuck (Marmota monax) and its HBV-like woodchuck hepatitis virus are a useful preclinical animal model for developing new therapeutic approaches in chronic hepadnaviral infections. Several innovative approaches combining antiviral treatments using nucleos(t)ide analogues, with prime-boost vaccination using DNA vaccines, new hepadnaviral antigens or recombinant adenoviral vectors were tested in the woodchuck model. In this review, we summarize these encouraging results obtained with these therapeutic vaccines. In addition, we present potential innovations in immunostimulatory strategies by blocking the interaction of the inhibitory programmed death receptor 1 with its ligand in this animal model.
has issue date	2014-12-23(xsd:dateTime)
bibo:doi	10.1007/s00430-014-0379-5
bibo:pmid	25535101
has license	no-cc
sha1sum (hex)	128fc4c67ef01890625e271452e1b9c7a4ac7984
schema:url	https://doi.org/10.1007/s00430-014-0379-5
resource representing a document's title	Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck
has PubMed Central identifier	PMC4305085
has PubMed identifier	25535101
schema:publication	Med Microbiol Immunol
resource representing a document's body	covid:128fc4c67ef01890625e271452e1b9c7a4ac7984#body_text
is schema:about of	named entity 'TREATMENT' named entity 'IMMUNOMODULATION' named entity 'THERAPEUTIC' named entity 'PRECLINICAL STUDIES' named entity 'VACCINATION' named entity 'BLOCKING' named entity 'DEATH RECEPTOR' named entity 'STRATEGIES' named entity 'INTERACTION' named entity 'ITS' named entity 'CHRONIC HEPATITIS B' named entity 'LIGAND' named entity 'INHIBITORY' named entity 'WOODCHUCK' named entity 'ANIMAL MODEL' covid:arg/128fc4c67ef01890625e271452e1b9c7a4ac7984 named entity 'strategies' named entity 'hepatitis B' named entity 'immunostimulatory' named entity 'woodchuck' named entity 'liver' named entity 'immunogenic' named entity 'viremia' named entity 'vaccination' named entity 'WHV' named entity 'lamivudine' named entity 'vaccine' named entity 'adaptive immune response' named entity 'CD28' named entity 'pathogens' named entity 'immunomodulatory' named entity 'infection' named entity 'PD-L1' named entity 'PBMCs' named entity 'infection' named entity 'chronic liver disease' named entity 'homologous' named entity 'liver' named entity 'immunization' named entity 'HBV' named entity 'vaccination' named entity 'amino acid sequences' named entity 'transcription' named entity 'Korea' named entity 'CHB' named entity 'infection' named entity 'HBV' named entity 'chronic HBV' named entity 'immune cells' named entity 'deep sequencing' named entity 'cell functions' named entity 'vector' named entity 'chronic hepatitis' named entity 'WHV' named entity 'amino acid residues' named entity 'HBsAg' named entity 'plasmid DNA' named entity 'cloned' named entity 'therapeutic approaches' named entity 'viral load' named entity 'antiviral treatment' named entity 'infection' named entity 'preclinical model' named entity 'gene expression' named entity 'innate immune responses' named entity 'immune tolerance' named entity 'APOBEC3' named entity 'humoral' named entity 'HBV' named entity 'viremia' named entity 'hepatotoxic' named entity 'infection' named entity 'HBV' named entity 'WHV' named entity 'HBV' named entity 'HBV' named entity 'dose-dependent' named entity 'peripheral blood'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software